| Xanthine Derivatives & Allied Products | Production of Xanthine derivatives such as caffeine, theophylline; largest capacity in India serving pharmaceutical and beverage sectors. | Backward integration, largest capacity in India, regulatory certifications (USFDA, EU GMP), and global client relationships. | Pharmaceutical companies and beverage manufacturers globally, including nutraceutical and energy drink producers. | Pharmaceutical grade Xanthine derivatives, specialty products with regulatory approvals. | 500 | 24 | Direct sales to global clients, long-term supply contracts, B2B model primarily with pharmaceutical and beverage companies. | Contract-based pricing with long-term supply agreements, volume discounts applied. | China+1 supply shifts, increased demand in pharma and beverage sectors, capacity expansion to 9,000 MTPA. | |
| Active Pharmaceutical Ingredients (API) and Intermediates | Manufacture of HPAPIs and intermediates for oncology, corticosteroids, and various chronic therapeutic areas with regulatory compliance. | USFDA, EDQM approvals; strong backward integration; proprietary processes; and dedicated manufacturing blocks. | Global generics and specialty pharma companies in regulated and non-regulated markets. | HPAPIs and specialized intermediates requiring complex synthesis and regulatory documentation. | 1100 | 52 | Sales via long-term contracts with pharmaceutical companies globally; B2B focused on regulated markets. | Contract manufacturing with fixed and variable pricing clauses based on volume and client specifications. | Robust regulatory approvals, strong R&D, growing demand for high-potency and specialty APIs. | |
| Contract Development and Manufacturing Organization (CDMO/CMO) | End-to-end process development and commercial manufacturing of KSMs, intermediates, and GMP APIs including novel chemistries. | Three R&D centers, pilot facilities, advanced process knowledge; strategic on-ground sales expansion in USA and EU. | Pharmaceutical innovators, biotech companies globally in clinical and commercial phases. | Early-phase clinical manufacturing and complex chemistry capabilities. | 500 | 24 | Project-based revenue from clinical to commercial supply contracts; service contracts with pharma innovators and biotech firms. | Project and milestone-based pricing, long-term supply agreements; service fees linked to development and manufacturing volumes. | Expanding pharmaceutical innovation, demand for specialized outsourced manufacturing, and pipeline growth. | |
